A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer

Trial Profile

A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Olaptesed pegol (Primary) ; Pembrolizumab (Primary)
  • Indications Colorectal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Keynote-559; OPERA
  • Sponsors NOXXON Pharma AG
  • Most Recent Events

    • 06 Apr 2017 Status changed from planning to recruiting.
    • 23 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top